Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), FiscalAI reports. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The business had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million.

Here are the key takeaways from Day One Biopharmaceuticals’ conference call:

• OJEMDA commercial traction: 2025 net product revenue was $155.4M (up 172% YoY) with Q4 revenue of $52.8M and >4,600 prescriptions; management reiterated 2026 OJEMDA guidance of $225M–$250M.
• Three‑year FIREFLY‑1 data strengthen clinical case: company reports a 53% objective response rate, median response duration ~19.4 months, no new safety signals, and a median time‑to‑next‑treatment (TTNT) of 42.6 months versus a 16.6‑month PFS, which management says supports durable clinical benefit.
• Pipeline and BD progress: acquisition of Mersana closed in January to add Emi‑Le (early activity in adenoid cystic carcinoma) with an updated dataset planned for mid‑2026 and potential accelerated development, plus DAY301 early signals expected H2 2026.
• Concentration and timing risks remain: Day One is heavily dependent on OJEMDA as its primary revenue driver and future performance hinges on persistence, new patient starts, payer dynamics, and successful enrollment/readout of FIREFLY‑2 (top‑line mid‑2027); statements are forward‑looking and company‑presented.

Day One Biopharmaceuticals Trading Down 9.7%

DAWN stock traded down $1.17 during midday trading on Wednesday, hitting $10.85. 2,272,648 shares of the company’s stock were exchanged, compared to its average volume of 2,453,015. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -7.16 and a beta of -1.26. The firm has a 50 day moving average price of $10.63 and a 200-day moving average price of $8.74. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $13.20.

Insiders Place Their Bets

In related news, CEO Jeremy Bender sold 15,459 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $179,324.40. Following the sale, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at $2,373,394.80. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Charles N. York II sold 6,065 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the sale, the chief financial officer directly owned 312,025 shares of the company’s stock, valued at $3,619,490. The trade was a 1.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of DAWN. Vestal Point Capital LP grew its holdings in shares of Day One Biopharmaceuticals by 94.4% during the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after purchasing an additional 2,525,000 shares during the last quarter. Deerfield Management Company L.P. grew its position in shares of Day One Biopharmaceuticals by 26.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after buying an additional 982,282 shares during the last quarter. State Street Corp increased its stake in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. State Street Corp now owns 4,289,566 shares of the company’s stock valued at $39,979,000 after buying an additional 1,049,122 shares during the period. Rubric Capital Management LP bought a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at about $23,808,000. Finally, Geode Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 1,877,838 shares of the company’s stock valued at $17,505,000 after acquiring an additional 116,574 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DAWN. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. HC Wainwright decreased their target price on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Wedbush upped their target price on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $26.14.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and reaffirmed 2026 outlook — Day One reported Q4 product revenue of ~$52.8M and full‑year 2025 net product revenue of $155.4M, beating consensus. Management reaffirmed 2026 U.S. net product revenue guidance of $225–$250M, which supports growth expectations. Press Release
• Positive Sentiment: Pipeline expansion via acquisition — The company completed the January acquisition of Mersana, adding Emi‑Le (Phase 1 for ACC) and expanding oncology pipeline optionality, a longer‑term positive for valuation if assets advance. Press Release
• Positive Sentiment: Wedbush raises price target — Wedbush bumped its PT from $29 to $30 and maintained an “outperform” call, implying meaningful upside versus current levels and giving bullish third‑party validation. Benzinga TickerReport
• Neutral Sentiment: Earnings materials and call transcripts available — Full Q4 slide deck and earnings‑call transcripts were posted (useful for digging into unit trends, OJEMDA uptake, and margin drivers). These provide detail but are not immediately price‑moving by themselves. Slide Deck Presentation
• Negative Sentiment: EPS miss and margins remain a concern — Reported EPS of ($0.21) missed the ($0.17) consensus and the company still shows negative net margin and ROE, fueling near‑term disappointment and selling pressure despite the revenue beat. MarketBeat
• Negative Sentiment: Mixed analyst reactions — While some firms raised targets, Needham cut its PT to $17 and HC Wainwright trimmed to $22 (both kept “buy”), reflecting differing views on near‑term profitability and risk; the cuts add downward pressure even as other shops remain constructive. Benzinga

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.